VIVUS Inc. (NASDAQ:VVUS) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.
VIVUS Inc. (NASDAQ:VVUS) gained 26.68 Percent and closed its previous trading session at $0.66. The stock traded with the average Volume of 783.4 Million at the end of last session.
The company reported its last earnings Actual EPS of $-0.1/share. While, the analyst predicted that the company could provide an EPS of $-0.13/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.03/share which shows an Earnings Surprise of 23.1 Percent.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 46.51% where SMA50 and SMA200 are 51.56% and 2.96% respectively.
The company shows its Return on Assets (ROA) value of -15.1%. The Return on Equity (ROE) value stands at 695.9%. While it’s Return on Investment (ROI) value is 1.2%.
VIVUS Inc. (NASDAQ:VVUS) currently has a Weekly Volatility of 12.96% percent while its Monthly Volatility is at 12.93% percent. While talking about Performance of the Stock, VIVUS Inc. currently has a Weekly performance of 34.72%, monthly performance percentage is 62.56 percent, Quarterly performance is 41.94 percent, 6 months performance shows a percent value of 2.72% and Yearly Performance is -34.65 percent.
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company’s lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS.